Trial Profile
A Double-blind, Randomized and Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of T89 in Prevention and Treatment of Acute Mountain Sickness (AMS) During Rapid Ascent
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs T 89 (Primary)
- Indications Altitude sickness
- Focus Therapeutic Use
- 11 Sep 2019 Planned number of patients changed from 120 to 130.
- 17 Aug 2018 New trial record